Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy
- PMID: 1949613
- DOI: 10.1007/BF01606522
Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy
Abstract
Immunohistochemical distribution of oestrogen receptors (ER), progesterone receptors (PR), and the cell proliferation-associated antigen Ki-67 was investigated in leiomyomas and the myometrium during the menstrual cycle and pregnancy. In the myometrium, ER expression was observed in the proliferative phase, but was suppressed in the secretory phase and during pregnancy. In leiomyomas, ER expression was observed throughout the menstrual cycle, but was suppressed during pregnancy. However, PR was expressed both in the myometrium and leiomyomas throughout the menstrual cycle and pregnancy. In both the myometrium and leiomyomas, a higher number of Ki-67-positive cells was observed during pregnancy than in the secretory phase, and Ki-67 was negative during menopause. The Ki-67-positive cell count in leiomyomas was significantly higher than that in the myometrium throughout the menstrual cycle and pregnancy. Thus both myometrium and leiomyomas have high growth activity under the hormonal milieu of high progesterone levels. The growth potential of leiomyomas is apparently higher than that of myometrium throughout the menstrual cycle and during pregnancy.
Similar articles
-
Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy.Hum Reprod. 1999 Nov;14(11):2844-50. doi: 10.1093/humrep/14.11.2844. Hum Reprod. 1999. PMID: 10548634
-
Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment.Acta Obstet Gynecol Scand. 2001 Jun;80(6):497-504. Acta Obstet Gynecol Scand. 2001. PMID: 11380284 Clinical Trial.
-
Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause.Acta Obstet Gynecol Scand. 2000 May;79(5):397-404. Acta Obstet Gynecol Scand. 2000. PMID: 10830768
-
Abnormal gene expression in uterine leiomyomas.J Soc Gynecol Investig. 1995 Sep-Oct;2(5):663-72. doi: 10.1016/1071-5576(95)00021-6. J Soc Gynecol Investig. 1995. PMID: 9420873 Review.
-
Growth factors and cytokines in uterine leiomyomas.Semin Reprod Endocrinol. 1996 Aug;14(3):269-82. doi: 10.1055/s-2007-1016336. Semin Reprod Endocrinol. 1996. PMID: 8885057 Review.
Cited by
-
Etiology and pathogenesis of uterine leiomyomas: a review.Environ Health Perspect. 2003 Jun;111(8):1037-54. doi: 10.1289/ehp.5787. Environ Health Perspect. 2003. PMID: 12826476 Free PMC article. Review.
-
Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation.Endocrinology. 2009 May;150(5):2436-45. doi: 10.1210/en.2008-0224. Epub 2009 Jan 29. Endocrinology. 2009. PMID: 19179429 Free PMC article.
-
Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.Endocr Rev. 2020 Oct 1;41(5):bnaa012. doi: 10.1210/endrev/bnaa012. Endocr Rev. 2020. PMID: 32365199 Free PMC article. Review.
-
Smooth muscle tumor of the placenta - an entrapped maternal leiomyoma: a case report.J Med Case Rep. 2009 Jun 17;3:7302. doi: 10.4076/1752-1947-3-7302. J Med Case Rep. 2009. PMID: 19830174 Free PMC article.
-
Role of nuclear progesterone receptor isoforms in uterine pathophysiology.Hum Reprod Update. 2015 Mar-Apr;21(2):155-73. doi: 10.1093/humupd/dmu056. Epub 2014 Nov 18. Hum Reprod Update. 2015. PMID: 25406186 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials